EMILE Version 1
Research type
Research Study
Full title
EMILE - Evaluation of the effect of Microbial dysbiosis upon anti-viral Immunity in bronchiEctasis
IRAS ID
330984
Contact name
Justin Garner
Contact email
Sponsor organisation
Guy's and St Thomas' NHS Foundation Trust
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
The lung ‘microbiome’ is the entire population of micro-organisms, bacteria, fungi, and viruses that reside within our lungs. Patient with chronic lung disease including bronchiectasis (a condition characterised by abnormally dilated airways) show outgrowth of certain bacteria within their microbiome. We do not know whether this outgrowth is just a consequence of the disease or if, by upsetting the immune system, these bacteria actually contribute to development and progression of the disease. Patients with chronic lung disease including bronchiectasis are also prone to developing infections by viruses that lead to acute symptom flare-ups ('exacerbations') and whether specific microbiome compositions can increase susceptibility to exacerbations is unknown.
We will use new sensitive techniques to characterise the microbiome in bronchiectasis and relate the changes we observe to progression of the disease and frequency of exacerbations. . It is anticipated pilot data from this study will improve our understanding of the mechanisms underlying these processes and assist with targeted drug development.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
23/PR/1158
Date of REC Opinion
14 Dec 2023
REC opinion
Further Information Favourable Opinion